Its reduced levels correlated with elevated levels of thrombosis markers (D-dimer), acute phase reactants (ferritin), and inflammatory modulators (HGF and IP-10), suggesting that strategies that increase citric acid levels could be protective for COVID-19 infected patients. The gene discussed is CXCL10; the disease is COVID-19.